Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
23Andme Holding Co.
(NQ:
ME
)
0.5452
-0.0130 (-2.33%)
Official Closing Price
Updated: 4:15 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 23Andme Holding Co.
< Previous
1
2
3
4
5
6
7
8
Next >
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
April 14, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
April 11, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
March 24, 2023
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers
From
23andMe Holding Co.
Via
GlobeNewswire
This Genetics Stock Could Have Massive Long-Term Potential
February 10, 2023
This healthcare company isn't without risk but is doing a good job executing on its vision.
Via
The Motley Fool
A Preview Of 23andMe Holding's Earnings
February 07, 2023
Via
Benzinga
3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks
March 22, 2023
Biotechs with an AI strategy are likely to be the first to flourish from the disruptions.
Via
The Motley Fool
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented
From
23andMe Holding Co.
Via
GlobeNewswire
AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023
March 09, 2023
They've been using machine learning for years, and now they might do even more.
Via
The Motley Fool
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
March 09, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise
March 02, 2023
There's nothing better than getting a bargain that'll pay off for years.
Via
The Motley Fool
2 High-Growth Stocks That Could Double Your Money in 5 Years or Less
February 28, 2023
Both are likely to double quite soon, and they aren't even that risky.
Via
The Motley Fool
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
February 28, 2023
The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and...
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe to Present at Upcoming Investor Conferences
February 22, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Why Tivic Health Systems Are Trading Lower By 55%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 09, 2023
Gainers Hempacco Co., Inc. (NASDAQ: HPCO) rose 296% to $2.99 after declining 6% on Wednesday.
Via
Benzinga
MGM Resorts, Madison Square Garden Entertainment, Cardiovascular Systems And Other Big Stocks Moving Higher On Thursday
February 09, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 08, 2023
Via
Benzinga
23andMe Reports FY2023 Third Quarter Financial Results
February 08, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
7 Former SPACs I Still Own (And What I Think Now)
January 28, 2023
Remember the SPAC boom? Here are seven products of that time that are still in my portfolio.
Via
The Motley Fool
23andMe to Report FY2023 Third Quarter Financial Results
January 26, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
3 Penny Stocks That Could Make You Filthy Rich
January 25, 2023
These low-priced equities could deliver enormous returns for risk-tolerant shareholders.
Via
The Motley Fool
My 4 Worst-Performing Stocks and What I Think Now
January 10, 2023
These stocks are all down 70% or more from what I paid.
Via
The Motley Fool
Stocks That Hit 52-Week Lows On Friday
January 06, 2023
During Friday's trading, 71 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
January 05, 2023
On Thursday, 63 companies set new 52-week lows.
Via
Benzinga
Guardant Health, Novavax And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
December 16, 2022
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
25 Meme Stocks to Sell Before They Die
December 15, 2022
Wondering what the best meme stocks to sell for 2023 are? Here are the top picks that investors should offload and avoid.
Via
InvestorPlace
The Worst Investment Decision I Made in 2022
December 10, 2022
The stock market has had a terrible year, and here are some moves we wish we could do over.
Via
The Motley Fool
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
December 05, 2022
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share.
Via
Benzinga
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
December 01, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022
November 29, 2022
Via
Benzinga
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
November 10, 2022
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.
Via
TheNewswire.com
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.